Skip to content

Use of medication for preventing diabetes in obese pregnant women

Use of metformin for the prevention of gestational diabetes mellitus in obese pregnant women - : Use of metformin for the prevention of gestational diabetes mellitus in obese pregnant women

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-9rpqdn
Enrollment
Unknown
Registered
2016-05-04
Start date
2014-10-31
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus arises during pregnancy. Pregnancy complications.

Interventions

Group Intervention: 104 pregnant women who will be randomized to 20 weeks of gestation, with a body mass index equal to or greater than 30 kg / m2, aged less than 18 years with screening for gestation
Drug

Sponsors

Universidade da Região de Joinville Univille
Lead Sponsor
Universidade da Região de Joinville Univille
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: With obesity diagnosis of pregnant women will be selected according to the criteria of the World Health Organization with BMI or greater than 30 kg / m2; aged over 18 years; singleton pregnancy; with screening for gestational diabetes mellitus (GDM) at the beginning of the negative pregnancy; gestational age less than 20 weeks; no pathology that interferes with glucose metabolism; no hypersensitivity to metformin hydrochloride or important drug allergy; history or presence of liver disease; renal or gastrointestinal or other conditions that interfere with the absorption, distribution, excretion or metabolism of the drug.

Exclusion criteria

Exclusion criteria: Losses following are deleted; intolerance drugs; desire of the pregnant woman; presence of risk to the fetus; allergy to metformin, mother's death and fetus.

Design outcomes

Primary

MeasureTime frame
Reduction of cases of Gestational Diabetes Mellitus in obese pregnant women who have made the use of metformin hydrochloride, 2 times a day (breakfast and dinner), the realization of the reduction will be performed by biochemical analysis through oral test of glucose tolerance (OGTT ) to be held over the gestational trimesters. It expects a 35% effectiveness in reducing cases of Gestational Diabetes Mellitus which will be proven through statistical tests and comparing the concentrations in the OGTT test and control groups.

Secondary

MeasureTime frame
Decreased neonatal hypoglycemia in infants of obese pregnant women who have made the use of metformin hydrochloride during pregnancy. For evaluation of this variable will be held plasma glucose dosage of newborns according to protocol guidelines of the Brazilian Society of Pediatrics. For realization of the expected outcomes will be performed statistical tests and comparing the concentrations of plasma glucose in babies of mothers of test and control groups.

Countries

Brazil

Contacts

Public ContactWillian Sales

Universidade da Região de Joinville Univille

sallesbio@hotmail.com+55 (41) 8859 9064

Outcome results

None listed

Source: REBEC (via WHO ICTRP)